Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Relationship of Serum Antileishmanial Antibody With Development of Visceral Leishmaniasis, Post-kala-azar Dermal Leishmaniasis and Visceral Leishmaniasis Relapse.

Mondal D, Ghosh P, Chowdhury R, Halleux C, Ruiz-Postigo JA, Alim A, Hossain F, Khan MAA, Nath R, Duthie MS, Kroeger A, Matlashewski G, Argaw D, Olliaro P.

Front Microbiol. 2019 Oct 9;10:2268. doi: 10.3389/fmicb.2019.02268. eCollection 2019.

2.

Single-Strand Annealing Plays a Major Role in Double-Strand DNA Break Repair following CRISPR-Cas9 Cleavage in Leishmania.

Zhang WW, Matlashewski G.

mSphere. 2019 Aug 21;4(4). pii: e00408-19. doi: 10.1128/mSphere.00408-19.

3.

Barriers of Visceral Leishmaniasis reporting and surveillance in Nepal: comparison of governmental VL-program districts with non-program districts.

Lim D, Banjara MR, Singh VK, Joshi AB, Gurung CK, Das ML, Matlashewski G, Olliaro P, Kroeger A.

Trop Med Int Health. 2019 Feb;24(2):192-204. doi: 10.1111/tmi.13189. Epub 2018 Dec 18.

PMID:
30565348
4.

Intervention Packages for Early Visceral Leishmaniasis Case Detection and Sandfly Control in Bangladesh: A Comparative Analysis.

Huda MM, Ghosh D, Alim A, Almahmud M, Olliaro PL, Matlashewski G, Kroeger A, Mondal D.

Am J Trop Med Hyg. 2019 Jan;100(1):97-107. doi: 10.4269/ajtmh.18-0290.

5.

Integrating Case Detection of Visceral Leishmaniasis and Other Febrile Illness with Vector Control in the Post-Elimination Phase in Nepal.

Banjara MR, Das ML, Gurung CK, Singh VK, Joshi AB, Matlashewski G, Kroeger A, Olliaro P.

Am J Trop Med Hyg. 2019 Jan;100(1):108-114. doi: 10.4269/ajtmh.18-0307.

6.

A complete Leishmania donovani reference genome identifies novel genetic variations associated with virulence.

Lypaczewski P, Hoshizaki J, Zhang WW, McCall LI, Torcivia-Rodriguez J, Simonyan V, Kaur A, Dewar K, Matlashewski G.

Sci Rep. 2018 Nov 8;8(1):16549. doi: 10.1038/s41598-018-34812-x.

7.

Evaluation of Real-time PCR for Diagnosis of Post-Kala-azar Dermal Leishmaniasis in Endemic Foci of Bangladesh.

Ghosh P, Hasnain MG, Hossain F, Khan MAA, Chowdhury R, Faisal K, Mural MA, Baker J, Nath R, Ghosh D, Maruf S, Shomik MS, Haque R, Matlashewski G, Hamano S, Duthie MS, Mondal D.

Open Forum Infect Dis. 2018 Sep 15;5(10):ofy234. doi: 10.1093/ofid/ofy234. eCollection 2018 Oct.

8.

Development of a sandwich ELISA to detect Leishmania 40S ribosomal protein S12 antigen from blood samples of visceral leishmaniasis patients.

Zhang WW, Ghosh AK, Mohamath R, Whittle J, Picone A, Lypaczewski P, Ndao M, Howard RF, Das P, Reed SG, Matlashewski G.

BMC Infect Dis. 2018 Oct 3;18(1):500. doi: 10.1186/s12879-018-3420-2.

9.

Atypical leishmaniasis: A global perspective with emphasis on the Indian subcontinent.

Thakur L, Singh KK, Shanker V, Negi A, Jain A, Matlashewski G, Jain M.

PLoS Negl Trop Dis. 2018 Sep 27;12(9):e0006659. doi: 10.1371/journal.pntd.0006659. eCollection 2018 Sep. Review.

10.

Towards elimination of visceral leishmaniasis in the Indian subcontinent-Translating research to practice to public health.

Hirve S, Kroeger A, Matlashewski G, Mondal D, Banjara MR, Das P, Be-Nazir A, Arana B, Olliaro P.

PLoS Negl Trop Dis. 2017 Oct 12;11(10):e0005889. doi: 10.1371/journal.pntd.0005889. eCollection 2017 Oct. Review.

11.

Investments in Research and Surveillance Are Needed to Go Beyond Elimination and Stop Transmission of Leishmania in the Indian Subcontinent.

Olliaro PL, Shamsuzzaman TA, Marasini B, Dhariwal AC, Be-Nazir A, Mondal D, Banjara MR, Das P, Sundar S, Rijal S, Arana B, Alvar J, Argaw D, Peeling RW, Kroeger A, Matlashewski G.

PLoS Negl Trop Dis. 2017 Jan 26;11(1):e0005190. doi: 10.1371/journal.pntd.0005190. eCollection 2017 Jan. No abstract available.

12.

Optimized CRISPR-Cas9 Genome Editing for Leishmania and Its Use To Target a Multigene Family, Induce Chromosomal Translocation, and Study DNA Break Repair Mechanisms.

Zhang WW, Lypaczewski P, Matlashewski G.

mSphere. 2017 Jan 18;2(1). pii: e00340-16. doi: 10.1128/mSphere.00340-16. eCollection 2017 Jan-Feb.

13.

Longitudinal Study of Transmission in Households with Visceral Leishmaniasis, Asymptomatic Infections and PKDL in Highly Endemic Villages in Bihar, India.

Das VN, Pandey RN, Siddiqui NA, Chapman LA, Kumar V, Pandey K, Matlashewski G, Das P.

PLoS Negl Trop Dis. 2016 Dec 14;10(12):e0005196. doi: 10.1371/journal.pntd.0005196. eCollection 2016 Dec.

14.

Entomological efficacy of durable wall lining with reduced wall surface coverage for strengthening visceral leishmaniasis vector control in Bangladesh, India and Nepal.

Huda MM, Kumar V, Das ML, Ghosh D, Priyanka J, Das P, Alim A, Matlashewski G, Kroeger A, Alfonso-Sierra E, Mondal D.

BMC Infect Dis. 2016 Oct 6;16(1):539.

15.

Efficacy, Safety and Cost of Insecticide Treated Wall Lining, Insecticide Treated Bed Nets and Indoor Wall Wash with Lime for Visceral Leishmaniasis Vector Control in the Indian Sub-continent: A Multi-country Cluster Randomized Controlled Trial.

Mondal D, Das ML, Kumar V, Huda MM, Das P, Ghosh D, Priyanka J, Matlashewski G, Kroeger A, Upfill-Brown A, Chowdhury R.

PLoS Negl Trop Dis. 2016 Aug 17;10(8):e0004932. doi: 10.1371/journal.pntd.0004932. eCollection 2016 Aug.

16.

Transmission Dynamics of Visceral Leishmaniasis in the Indian Subcontinent - A Systematic Literature Review.

Hirve S, Boelaert M, Matlashewski G, Mondal D, Arana B, Kroeger A, Olliaro P.

PLoS Negl Trop Dis. 2016 Aug 4;10(8):e0004896. doi: 10.1371/journal.pntd.0004896. eCollection 2016 Aug. Review.

18.

Mobile suitcase laboratory for rapid detection of Leishmania donovani using recombinase polymerase amplification assay.

Mondal D, Ghosh P, Khan MA, Hossain F, Böhlken-Fascher S, Matlashewski G, Kroeger A, Olliaro P, Abd El Wahed A.

Parasit Vectors. 2016 May 13;9(1):281. doi: 10.1186/s13071-016-1572-8.

19.

Repeated training of accredited social health activists (ASHAs) for improved detection of visceral leishmaniasis cases in Bihar, India.

Das VN, Pandey RN, Kumar V, Pandey K, Siddiqui NA, Verma RB, Matlashewski G, Das P.

Pathog Glob Health. 2016;110(1):33-5. doi: 10.1080/20477724.2016.1156902.

20.

CRISPR-Cas9-Mediated Genome Editing in Leishmania donovani.

Zhang WW, Matlashewski G.

MBio. 2015 Jul 21;6(4):e00861. doi: 10.1128/mBio.00861-15.

21.

Development of Leishmania vaccines in the era of visceral leishmaniasis elimination.

Engwerda CR, Matlashewski G.

Trans R Soc Trop Med Hyg. 2015 Jul;109(7):423-4. doi: 10.1093/trstmh/trv039. Epub 2015 Jun 4.

PMID:
26048873
22.

Adaptation of Leishmania donovani to cutaneous and visceral environments: in vivo selection and proteomic analysis.

McCall LI, Zhang WW, Dejgaard K, Atayde VD, Mazur A, Ranasinghe S, Liu J, Olivier M, Nilsson T, Matlashewski G.

J Proteome Res. 2015 Feb 6;14(2):1033-59. doi: 10.1021/pr5010604. Epub 2015 Jan 13.

PMID:
25536015
23.

Research priorities for elimination of visceral leishmaniasis.

Matlashewski G, Arana B, Kroeger A, Be-Nazir A, Mondal D, Nabi SG, Banjara MR, Das ML, Marasini B, Das P, Medley G, Satoskar A, Nakhasi H, Argaw D, Reeder J, Olliaro P.

Lancet Glob Health. 2014 Dec;2(12):e683-4. doi: 10.1016/S2214-109X(14)70318-3. No abstract available.

24.

Screening Leishmania donovani complex-specific genes required for visceral disease.

Zhang WW, Matlashewski G.

Methods Mol Biol. 2015;1201:339-61. doi: 10.1007/978-1-4939-1438-8_20.

PMID:
25388124
25.

Asymptomatic Leishmania infections in northern India: a threat for the elimination programme?

Das S, Matlashewski G, Bhunia GS, Kesari S, Das P.

Trans R Soc Trop Med Hyg. 2014 Nov;108(11):679-84. doi: 10.1093/trstmh/tru146. Epub 2014 Sep 9. Review.

PMID:
25205664
26.

Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility study.

Mondal D, Alvar J, Hasnain MG, Hossain MS, Ghosh D, Huda MM, Nabi SG, Sundar S, Matlashewski G, Arana B.

Lancet Glob Health. 2014 Jan;2(1):e51-7. doi: 10.1016/S2214-109X(13)70118-9. Epub 2013 Dec 5.

27.

Accelerated active case detection of visceral leishmaniasis patients in endemic villages of Bangladesh.

Khatun J, Huda MM, Hossain MS, Presber W, Ghosh D, Kroeger A, Matlashewski G, Mondal D.

PLoS One. 2014 Aug 4;9(8):e103678. doi: 10.1371/journal.pone.0103678. eCollection 2014.

28.

Genetic analysis of Leishmania donovani tropism using a naturally attenuated cutaneous strain.

Zhang WW, Ramasamy G, McCall LI, Haydock A, Ranasinghe S, Abeygunasekara P, Sirimanna G, Wickremasinghe R, Myler P, Matlashewski G.

PLoS Pathog. 2014 Jul 3;10(7):e1004244. doi: 10.1371/journal.ppat.1004244. eCollection 2014 Jul.

29.

Impact of ASHA training on active case detection of visceral leishmaniasis in Bihar, India.

Das VN, Pandey RN, Pandey K, Singh V, Kumar V, Matlashewski G, Das P.

PLoS Negl Trop Dis. 2014 May 22;8(5):e2774. doi: 10.1371/journal.pntd.0002774. eCollection 2014 May.

30.

A2 and other visceralizing proteins of Leishmania: role in pathogenesis and application for vaccine development.

Fernandes AP, Canavaci AM, McCall LI, Matlashewski G.

Subcell Biochem. 2014;74:77-101. doi: 10.1007/978-94-007-7305-9_3. Review.

PMID:
24264241
31.

Cross-sectional study to assess risk factors for leishmaniasis in an endemic region in Sri Lanka.

Ranasinghe S, Wickremasinghe R, Munasinghe A, Hulangamuwa S, Sivanantharajah S, Seneviratne K, Bandara S, Athauda I, Navaratne C, Silva O, Wackwella H, Matlashewski G, Wickremasinghe R.

Am J Trop Med Hyg. 2013 Oct;89(4):742-9. doi: 10.4269/ajtmh.12-0640. Epub 2013 Aug 5.

32.

One More Death from Visceral Leishmaniasis Has Gone by Unnoticed. What Can Be Done?

Matlashewski G, Pandey R, Das V, Das P.

PLoS Negl Trop Dis. 2013 Jun 27;7(6):e2082. Print 2013 Jun. No abstract available.

33.

Reducing visceral leishmaniasis by insecticide impregnation of bed-nets, Bangladesh.

Mondal D, Huda MM, Karmoker MK, Ghosh D, Matlashewski G, Nabi SG, Kroeger A.

Emerg Infect Dis. 2013 Jul;19(7):1131-4. doi: 10.3201/eid1907.120932.

34.

Diagnosis of visceral leishmaniasis in Bihar India: comparison of the rK39 rapid diagnostic test on whole blood versus serum.

Matlashewski G, Das VN, Pandey K, Singh D, Das S, Ghosh AK, Pandey RN, Das P.

PLoS Negl Trop Dis. 2013 May 23;7(5):e2233. doi: 10.1371/journal.pntd.0002233. Print 2013.

35.

A FRET-based real-time PCR assay to identify the main causal agents of New World tegumentary leishmaniasis.

Tsukayama P, Núñez JH, De Los Santos M, Soberón V, Lucas CM, Matlashewski G, Llanos-Cuentas A, Ore M, Baldeviano GC, Edgel KA, Lescano AG, Graf PC, Bacon DJ.

PLoS Negl Trop Dis. 2013;7(1):e1956. doi: 10.1371/journal.pntd.0001956. Epub 2013 Jan 3.

36.

Determinants for the development of visceral leishmaniasis disease.

McCall LI, Zhang WW, Matlashewski G.

PLoS Pathog. 2013 Jan;9(1):e1003053. doi: 10.1371/journal.ppat.1003053. Epub 2013 Jan 3. Review.

37.

Leishmania donovani zymodeme MON-37 isolated from an autochthonous visceral leishmaniasis patient in Sri Lanka.

Ranasinghe S, Zhang WW, Wickremasinghe R, Abeygunasekera P, Chandrasekharan V, Athauda S, Mendis S, Hulangamuwa S, Matlashewski G, Pratlong F.

Pathog Glob Health. 2012 Nov;106(7):421-4. doi: 10.1179/2047773212Y.0000000054.

38.

Leishmanization revisited: immunization with a naturally attenuated cutaneous Leishmania donovani isolate from Sri Lanka protects against visceral leishmaniasis.

McCall LI, Zhang WW, Ranasinghe S, Matlashewski G.

Vaccine. 2013 Feb 27;31(10):1420-5. doi: 10.1016/j.vaccine.2012.11.065. Epub 2012 Dec 7.

PMID:
23219435
39.

Role of cytosolic glyceraldehyde-3-phosphate dehydrogenase in visceral organ infection by Leishmania donovani.

Zhang WW, McCall LI, Matlashewski G.

Eukaryot Cell. 2013 Jan;12(1):70-7. doi: 10.1128/EC.00263-12. Epub 2012 Nov 2.

40.

Deletion of an ATP-binding cassette protein subfamily C transporter in Leishmania donovani results in increased virulence.

Zhang WW, Matlashewski G.

Mol Biochem Parasitol. 2012 Oct;185(2):165-9. doi: 10.1016/j.molbiopara.2012.07.006. Epub 2012 Jul 27.

PMID:
22841683
41.

Adjuvants for Leishmania vaccines: from models to clinical application.

Raman VS, Duthie MS, Fox CB, Matlashewski G, Reed SG.

Front Immunol. 2012 Jun 11;3:144. doi: 10.3389/fimmu.2012.00144. eCollection 2012.

42.

Involvement of the Leishmania donovani virulence factor A2 in protection against heat and oxidative stress.

McCall LI, Matlashewski G.

Exp Parasitol. 2012 Oct;132(2):109-15. doi: 10.1016/j.exppara.2012.06.001. Epub 2012 Jun 9.

PMID:
22691540
43.

Expression of a Leishmaniadonovani nucleotide sugar transporter in Leishmaniamajor enhances survival in visceral organs.

Zhang WW, Chan KF, Song Z, Matlashewski G.

Exp Parasitol. 2011 Dec;129(4):337-45. doi: 10.1016/j.exppara.2011.09.010. Epub 2011 Sep 29.

PMID:
21978449
44.

Intracellular eukaryotic parasites have a distinct unfolded protein response.

Gosline SJ, Nascimento M, McCall LI, Zilberstein D, Thomas DY, Matlashewski G, Hallett M.

PLoS One. 2011 Apr 29;6(4):e19118. doi: 10.1371/journal.pone.0019118.

45.

Generation and evaluation of A2-expressing Lactococcus lactis live vaccines against Leishmania donovani in BALB/c mice.

Yam KK, Hugentobler F, Pouliot P, Stern AM, Lalande JD, Matlashewski G, Olivier M, Cousineau B.

J Med Microbiol. 2011 Sep;60(Pt 9):1248-60. doi: 10.1099/jmm.0.029959-0. Epub 2011 Apr 28.

PMID:
21527547
46.

Visceral leishmaniasis: elimination with existing interventions.

Matlashewski G, Arana B, Kroeger A, Battacharya S, Sundar S, Das P, Sinha PK, Rijal S, Mondal D, Zilberstein D, Alvar J.

Lancet Infect Dis. 2011 Apr;11(4):322-5. doi: 10.1016/S1473-3099(10)70320-0. Review.

PMID:
21453873
47.

Analysis of the PDZ binding specificities of Influenza A virus NS1 proteins.

Thomas M, Kranjec C, Nagasaka K, Matlashewski G, Banks L.

Virol J. 2011 Jan 19;8:25. doi: 10.1186/1743-422X-8-25.

48.

Screening Leishmania donovani-specific genes required for visceral infection.

Zhang WW, Matlashewski G.

Mol Microbiol. 2010 Jul;77(2):505-17. doi: 10.1111/j.1365-2958.2010.07230.x. Epub 2010 Jun 1.

49.

Localization and induction of the A2 virulence factor in Leishmania: evidence that A2 is a stress response protein.

McCall LI, Matlashewski G.

Mol Microbiol. 2010 Jul;77(2):518-30. doi: 10.1111/j.1365-2958.2010.07229.x. Epub 2010 May 24.

50.

First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony.

Miranda-Verastegui C, Tulliano G, Gyorkos TW, Calderon W, Rahme E, Ward B, Cruz M, Llanos-Cuentas A, Matlashewski G.

PLoS Negl Trop Dis. 2009 Jul 28;3(7):e491. doi: 10.1371/journal.pntd.0000491.

Supplemental Content

Loading ...
Support Center